Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Respon	ises)		1									
1. Name and Address of Reporting Person *- BUCALO LOUIS R MD			2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTP]					IC	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ Officer (give title Other (specify below)			
C/O TITAN PHAI INC, 400 OYSTE	3. Date of Earliest Transaction (Month/Day/Year) 11/01/2005						below) President & CEO					
S SAN FRANCISO	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Benef							Beneficially	Owned				
,	2. Transaction Date (Month/Day/Year)	Exec	Deemed ution Date, if nth/Day/Year)	on Date, if Code Code Clastr. 8) (Instr. 8) (Instr. 3, 4 and 5) (Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	11/01/2005			P		914	A	\$ 1.66	497,400	D		
Common Stock	ommon Stock 11/01/2005			P		2,600	A	\$ 1.67	500,000	D		
Reminder: Report on a directly or indirectly.	a separate line for ea	ch cla	ass of securities	s benefic	,							
								SEC 1474 (9-02)				

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 $(\textit{e.g.}, \, \texttt{puts}, \, \texttt{calls}, \, \texttt{warrants}, \, \texttt{options}, \, \texttt{convertible} \, \texttt{securities})$

1. Title of	2.	3. Transaction	3A. Deemed	4.	5.		6. Date Exer	rcisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transactio	n Nu	mber	and Expirati	on Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	of		(Month/Day	/Year)	Unde	erlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Dei	rivative			Secu	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative				Sec	urities			(Inst	. 3 and		Owned	Security:	(Instr. 4)
	Security				Ac	quired			4)			Following	Direct (D)	
					(A)	or						Reported	or Indirect	
					Dis	posed						Transaction(s)	(I)	
					of (D)						(Instr. 4)	(Instr. 4)	
					(In:	str. 3,								
					4, a	nd 5)								
										Amount				
							Date	Expiration		or				
							Exercisable		Title	Number				
							Exercisable	Date		of				
				Code V	(A	(D)				Shares				

Reporting Owners

Bon ording Overnor Norms / Address		Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
BUCALO LOUIS R MD									
C/O TITAN PHARMACEUTICALS INC	X		President & CEO						
400 OYSTER POINT BLVD	Λ		r resident & CEO						
S SAN FRANCISCO, CA 94080									

Signatures

/s/ Louis R. Bucalo	11/01/2005
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.